« prev   random   next »



By mell following x   2017 Nov 3, 7:37am 403 views   2 comments   watch   sfw   quote     share    

Just received CRL from FDA for XYOSTED, their injectable testosterone, price crashed from almost $4 to sub $2. 50MM+ sales and rising, possible approval of generic epi-pen version in partnership w/ TEVA (ATRS supplies injectors). Risks are possible dilution (already bloated share count) if turnaround to profitability is delayed too much, otherwise this should slowly churn towards profitability within the next 1-2 years. Any movement on the CRL without the requirement of additional trials or approval of TEVAs generic epi-pen will send this soaring. Market cap just below 300MM, target market cap 700MM-1bln.

1   mell   ignore (1)   2018 Feb 14, 3:48pm   ↑ like (0)   ↓ dislike (0)     quote      

AMAG just got approval in partnership with ATRS for Makena injection. up $20-30% from it's sub $2 lows. Good stock going forward. More news to come as they meet with FDA 02/21 wrt Xyosted CRL.
2   HEYYOU   ignore (6)   2018 Feb 14, 6:19pm   ↑ like (0)   ↓ dislike (0)     quote      

Real men sweat testosterone!

Comment as anon_04eea or log in at top of page: